University Health Network
Rhelion to Supply Psilocybin for Parkinson’s Depression Trial
Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF) said its wholly owned subsidiary, Filament Health Corp., has entered a license agreement with Toronto’s University Health Network to supply PEX010 for a randomized clinical trial studying psilocybin as a potential treatment for depression in people with Parkinson’s disease. The investigator-initiated study, called PSI-PARK, will be sponsored…
